Sabrina Varga, MD
Family Medicine · Kinsman, OHNPI 1427024769
Payments from drug & device makers
Across 220 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$951
- Novo Nordisk$326
- AstraZeneca$266
- Astellas Pharma US Inc$266
- GSK$236
- Pfizer$225
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,891100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $951 |
| Novo Nordisk | 23 | $326 |
| AstraZeneca | 18 | $266 |
| Astellas Pharma US Inc | 10 | $266 |
| GSK | 16 | $236 |
| Pfizer | 12 | $225 |
| Abbott | 9 | $203 |
| Boehringer Ingelheim | 12 | $179 |
| Lilly USA, LLC | 9 | $157 |
| Johnson & Johnson | 10 | $154 |
| Amarin Pharma, Inc. | 9 | $133 |
| Amgen(2 entities) | 7 | $106 |
| Novartis | 5 | $74 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $52 |
| Inspire Medical Systems, Inc. | 2 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Lundbeck LLC | 2 | $45 |
| Merck | 3 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $40 |
| Esperion Therapeutics, Inc. | 2 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$3,891 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $103,891 |
| OzempicSemaglutide | 90 | $101,149 |
| TrulicityDulaglutide | 63 | $75,571 |
| XareltoRivaroxaban | 33 | $49,723 |
| FarxigaDapagliflozin Propanediol | 37 | $41,092 |
| MounjaroTirzepatide | 31 | $37,475 |
| JardianceEmpagliflozin | 27 | $24,560 |
| MyrbetriqMirabegron | 25 | $23,012 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $20,002 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $19,957 |
| LinzessLinaclotide | 28 | $19,370 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $12,201 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,637 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $10,538 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $10,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $157 | $113,04694 claims |
| PfizerEliquis | $225 | $103,891114 claims |
| Novo NordiskOzempic | $326 | $101,14990 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $266 | $73,29695 claims |
| Johnson & JohnsonXarelto | $154 | $49,72333 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $236 | $43,53181 claims |
| Boehringer IngelheimJardiance | $179 | $24,56027 claims |
| Astellas Pharma US IncMyrbetriq | $266 | $23,01225 claims |
| AbbVieLinzess, Synthroid | $951 | $21,06777 claims |
| MerckJanuvia | $45 | $7,70613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Kinsman
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.